Home>Corporate>History

History

  • The HLX01 (rituximab injection) of Shanghai Henlius approved for marketing at the beginning of 2019, becoming the first biosimilar drug in China.

  • FCN-159 tablet, a new drug of a subsidiary of Fosun Pharma, was approved by the State Food and Drug Administration for clinical trials of advanced solid tumors.

  • Fosun Pharma cooperated with Marubeni to develop the third-party healthcare market.

  • Fosun Pharma invested US$106 million in Butterfly Network, Inc., for development of smartphone ultrasound imager.

  • SPAQ-CO® Disp, a malaria prevention drug for children of Fosun Pharma, was pre-certified by the World Health Organization.

    Fosun Pharma被認定為上海市企業技術中心

    2011年

    Fosun Pharma獲上海普陀區科技系統先進基層黨組織獎項

    1998-2000年

    Fosun Pharma獲創稅千萬元企業獎項

    1999年

    Fosun Pharma獲1999年中證亞商中國最具發展潛力上市50強企業獎

    1999年7月

    Fosun Pharma獲普陀區先進黨組織獎

    2000年